You are here: Industry Insights > Market News > Virafin from Zydus Cadila priced at Rs 11,995 per dose

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Vibegron Intermediate CAS:1421271-01-3

Food Grade Fish Collagen

Vibegron Intermediate CAS:1295539-30-8

Vibegron Intermediate CAS:1426235-01-9

Vibegron Intermediate CAS:163625-46-5

Vibegron Intermediate

Virafin from Zydus Cadila priced at Rs 11,995 per dose

expresspharmaMay 12, 2021

Tag: Zydus Cadila , Virafin , COVID-19 , DCGI

Favorites

As per reports, Zydus Cadila has fixed the price of Virafin, a medicine that has received EUA for COVID-19 treatment, at Rs 11,995 per dose. Reportedly, the company has commenced dispatching the drug which can reportedly reduce oxygen support in COVID-19 patients.

Virafin from Zydus Cadila priced at Rs 11,995 per dose

The Drug Controller General of India (DCGI) gave emergency authorisation for restricted use to Virafin, a single-use therapy, on April 23.

Technically known as Pegylated Interferon alpha-2b, it is used to treat moderate infection of COVID-19. The company has said, “91.15 per cent of patients treated with PegIFN were RT-PCR negative by day 7.”

Previous:Woodstock Sterile Solutions Names Oliver Vogt as VP and General Manager

Next:Kejriwal asks PM to share vaccine formula with pharma firms to ramp up manufacturing

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Virafin from Zydus Cadila priced at Rs 11,995 per dose | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

Virafin from Zydus Cadila priced at Rs 11,995 per dose

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may like
More>>

Virafin from Zydus Cadila priced at Rs 11,995 per dose

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

You may likeMore>>

You may like
More>>